In a note distributed to clients and investors on February 8th, research analysts at Cantor Fitzgerald lowered their estimates for the earnings per share generated by the sale of Intra-Cellular Therapies shares.
The note referred to Intra-Cellular Therapies, INC (ITCI), and it discussed the fiscal year 2022 of the company.
In 2018, C.
Duncan, an analyst at Cantor Fitzgerald, anticipates that the biopharmaceutical business will earn $2.75 per share, which is a decrease from the previous forecast, which anticipated that the business would earn $2.74 per share in 2018. Cantor Fitzgerald has an “overweight” rating on the stock and an 83-dollar price target.
The firm also has a price target for the stock.
The current estimate for Intra-Cellular Therapies’ earnings per share for the full year is $2.86.
This estimate is based on the company’s historical performance.
In addition, Cantor Fitzgerald predicted that Intra-Cellular Therapies would have $0.92 per share earnings for the fiscal year 2023.
These earnings were projected for the company.
On Monday, the cost of purchasing a share of ITCI stock was $486.67 per share.
The company has a price-to-earnings ratio of -14.66, a beta value of 1.10, and a market capitalization of $4.61 billion.
The 50-day and the 200-day simple moving averages for the share price are currently at $50.21.
The same can be said for the 200-day simple moving average. Over the previous year, the cost of intra-cellular therapies ranged anywhere from $42.42 to $65.00 per treatment.
The price as of right now is $65.00.
Additional equity analysts have also published reports on the stock in question within the past few months.
Intra-Cellular Therapies’ stock was given a “buy” rating by Needham & Company LLC in a research note published on Friday.
The firm also set a target price of $70.00 for the company’s common stock.
In a research note published on Friday, November 4th, Canaccord Genuity Group increased their price objective on shares of Intra-Cellular Therapies from $90.00 to $93.00.
The outlook for the company was discussed in the note.
Last but not least, StockNews.com shifted its rating of shares of Intra-Cellular Therapies from “sell” to “hold” in a research report that was published on November 4th. Five market watchers currently have a “buy” rating on the stock, while only three currently have a “hold” rating on the stock. On Bloomberg.com, the stock of Intra-Cellular Therapies has been given a “Moderate Buy” recommendation on average, and the website’s analysts have projected that the price of the company’s stock will reach $71.38 shortly.
On December 1st, Michael Halstead, the company’s Executive Vice President, sold 50,000 shares of the company’s stock.
This is another development that is related to this topic.
The total amount received for the sale of the shares was $2,686,500.00, which works out to a price of $53.73 per share on average. You can read the transaction’s legal document submitted to the Securities and Exchange Commission by clicking on the link. Sharon Mates, the company’s Chief Executive Officer, recently sold 33,083 shares of company stock on Tuesday, December 13th, according to additional news concerning this topic.
A total of 1,819,565.00 worth of shares changed hands in the market, and the average price per share was $55. When the transaction is finalized, the Chief Executive Officer will become the owner of 1,100,309 shares, which are worth $60,516,995. Follow the link, which will take you to a filing submitted to the Securities and Exchange Commission. You will have the opportunity to acquire additional information regarding the transaction.
In addition, on December 1st, Michael Halstead Halstead, Executive Vice President of the company, sold 50,000 shares of the company’s stock.
The total amount received for the sale of the shares was $2,686,500.00, which works out to a price of $53.73 per share on average.
The disclosure about the purchase can be found in this particular location. Over the past three months, company insiders have been selling stock.
Leave a comment